# Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients

> **NCT01326546** · PHASE2 · COMPLETED · sponsor: **Chongqing Jiachen Biotechnology Ltd.** · enrollment: 378 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** Therapeutic HBV vaccine
- **DRUG:** entecavir
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01326546
- **Lead sponsor:** Chongqing Jiachen Biotechnology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 378 (ACTUAL)
- **Last updated:** 2019-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01326546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01326546, "Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01326546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*